Ovid Therapeutics Profit Margin

Ovid Therapeutics (OVID) currently reports a profit margin of -2178.84% as of June 2026. That compares with -574.02% in the prior-year period — down 279.6% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Ovid Therapeutics's profit margin history and peer comparisons.

Ovid Therapeutics's profit margin decreased from -574.02% to -2178.84% — a 279.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ovid Therapeutics's profit margin of -2178.84% is lower than the Healthcare sector average of 14.34%. That is roughly 15289.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Ovid Therapeutics's current -2178.84% should be judged against Healthcare norms (sector average: 14.34%) and against OVID's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2178.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Ovid Therapeutics, and consider following OVID for alerts when major investors trade the stock.